Pfizer consents to purchase Seagen for $43 billion.

Pfizer has consented to pay USD 43 billion for biotech Seagen and its spearheading class of designated disease sedates.

Under the terms, Pfizer would pay USD 229 an offer in real money, the drugmaker said on Monday.

Pfizer rose 2.7 percent on the New York Stock Trade.